Related Experiment Video
Updated: Sep 22, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical
Stefania Angela Di Fusco1, Edoardo Gronda2, Edoardo Mocini3
1Dipartimento Emergenza e Accettazione, U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri-ASL Roma 1, Martinotti Street 20, 00135 Rome, Italy.
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the presence of diabetes. Since these drugs have only recently been included among the four pillars of HFrEF treatment, cardiologists are still unfamiliar with their use in this setting. This article provides an up-to-date practical guide for the initiation and monitoring of patients treated with SGLT2 inhibitors.
More Related Videos
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Secondary Active Transport

